Bupivacaine/epinephrine/dexamethasone — Competitive Intelligence Brief

Bupivacaine/epinephrine/dexamethasone (Bupivacaine/epinephrine/dexamethasone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic combination. Area: Anesthesia/Pain Management.

marketed Local anesthetic combination Voltage-gated sodium channels (bupivacaine); alpha-1 adrenergic receptors (epinephrine); glucocorticoid receptor (dexamethasone) Anesthesia/Pain Management Small molecule

Target snapshot

Bupivacaine/epinephrine/dexamethasone (Bupivacaine/epinephrine/dexamethasone) — Cedars-Sinai Medical Center. This is a combination injection containing bupivacaine (local anesthetic), epinephrine (vasoconstrictor), and dexamethasone (corticosteroid) that blocks nerve conduction, maintains local drug concentration, and reduces inflammation at the injection site.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bupivacaine/epinephrine/dexamethasone TARGET	Bupivacaine/epinephrine/dexamethasone	Cedars-Sinai Medical Center	marketed	Local anesthetic combination	Voltage-gated sodium channels (bupivacaine); alpha-1 adrenergic receptors (epinephrine); glucocorticoid receptor (dexamethasone)
Hydrocortisone acetate and lidocaine hydrochloride	Hydrocortisone acetate and lidocaine hydrochloride	Citius Pharmaceuticals, Inc.	marketed	Topical corticosteroid and local anesthetic combination	Glucocorticoid receptor (hydrocortisone); voltage-gated sodium channels (lidocaine)
Normal saline, Lidocaine, dexmetomidine	Normal saline, Lidocaine, dexmetomidine	Kasr El Aini Hospital	marketed	Local anesthetic combination with sedative-analgesic agent	Voltage-gated sodium channels (lidocaine); alpha-2 adrenergic receptors (dexmedetomidine)
Lidocaine 7% + Tetracaine 7% cream	Lidocaine 7% + Tetracaine 7% cream	Galderma R&D	marketed	Local anesthetic combination	Voltage-gated sodium channels
Triamcinolone + Lidocaine	Triamcinolone + Lidocaine	MetroHealth Medical Center	marketed	Corticosteroid + Local anesthetic combination	Glucocorticoid receptor (triamcinolone); voltage-gated sodium channels (lidocaine)
Remifentanil+Lidocaine	Remifentanil+Lidocaine	The First Affiliated Hospital of Zhengzhou University	marketed	Opioid analgesic + Local anesthetic combination	Mu-opioid receptor (remifentanil); Voltage-gated sodium channels (lidocaine)
CT-guided corticosteroid+ bupivicaine	CT-guided corticosteroid+ bupivicaine	Montefiore Medical Center	marketed	Corticosteroid + local anesthetic combination injection

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic combination class)

1. University of Belgrade · 2 drugs in this class
2. Cedars-Sinai Medical Center · 1 drug in this class
3. Cutia Therapeutics（Wuxi）Co.,Ltd · 1 drug in this class
4. East Carolina University · 1 drug in this class
5. Galderma R&D · 1 drug in this class
6. Hadassah Medical Organization · 1 drug in this class
7. University of Alabama at Birmingham · 1 drug in this class
8. University of New Mexico · 1 drug in this class
9. Ain Shams University · 1 drug in this class
10. University of Wisconsin, Madison · 1 drug in this class